Market Overview - The A-share market continued to rise, with the Shanghai Composite Index achieving a 13-day winning streak, closing at 4083 points, up 1.5% [1] - The total market turnover reached 2.83 trillion yuan, an increase of 265 billion yuan from the previous trading day, with over 4100 stocks rising and nearly 150 stocks hitting the daily limit [1] Sector Performance - The brain-computer interface sector saw significant gains, with stocks like Sanbo Brain Science and Weisi Medical hitting the daily limit [2][4] - The titanium dioxide sector also experienced a collective price increase, with companies like Anning Shares and Vanadium Titanium Shares reaching the daily limit [2][6] - Brokerage stocks rose, with Huashan Securities and Hualin Securities hitting the daily limit [2][8] - Other sectors that performed well included industrial metals, silicon energy, electronic paper, and chemical raw materials [2] Brain-Computer Interface Sector - The brain-computer interface sector was particularly strong, with stocks like Beiyikang and Weisi Medical seeing gains of around 20% [5] - Elon Musk announced that Neuralink, his brain-computer interface company, plans to start large-scale production in 2026, which has positively impacted the sector [4] Titanium Dioxide Sector - The titanium dioxide industry recently issued a price increase notice to reverse previous low pricing and low profitability, indicating a potential recovery in industry profits [6] - Major domestic titanium dioxide companies are accelerating the layout of chloride process capacity, with Tianyuan Co. announcing a 1.48 billion yuan investment in a new project [6] Brokerage Sector - The brokerage sector is benefiting from high market activity, with the Shanghai Composite Index recording a 12-day winning streak and turnover exceeding 1 trillion yuan [8] - Analysts suggest that the improved policy environment and influx of funds will enhance the investment value of the brokerage sector, supporting growth in wealth management and self-operated business revenues [8] Industrial Metals Sector - The industrial metals sector is experiencing price increases driven by both financial and commodity attributes, with low global copper and aluminum inventories and expected demand growth from the recovering Chinese economy [12] - Stocks like Liyuan Shares and Chang Aluminum have seen significant gains, with some hitting the daily limit [13] Electronic Paper Sector - The electronic paper sector is also on the rise, with Su Dawei and other companies achieving substantial gains following a collaboration announcement with Shanghai Yudi Optoelectronics [14][15]

另外，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688580 | 伟思医疗 | 1 | 20.01 | 66.75亿 | 44.01 | | 301293 | 三博脑科 | 1 | 20.01 | 175亿 | 44.01 | | 688626 | 翔宇医疗 | 1 | 20.00 | 139亿 | 44.00 | | 300753 | 爰朋医疗 | 1 | 20.00 | 50.37 乙 | 44.00 | | 301330 | 熵基科技 | 1 | 19.99 | 112亿 | 43.99 | | 301363 | 美好医疗 | 1 | 19.99 | 197亿 | 43.99 | | 688273 | 麦澜德 | 1 | 19.99 | 61.22 亿 | 43.98 | | 300430 | 诚益通 | 1 | 18.47 | 74.60亿 | 42.14 | | 30040 ...

Market Performance - The Shanghai Composite Index rose by 1.14% to 4069.38 points, reaching a new high in over 10 years [1] - The Shenzhen Component Index increased by 0.81% to 13940.24 points, while the ChiNext Index fell by 0.04% to 3293.18 points [1] - The total trading volume in the Shanghai and Shenzhen markets was 178.13 billion yuan, with over 3600 stocks rising [1] Sector Performance - The leading sectors included brain-computer interfaces, chemical engineering, non-ferrous metals, insurance, securities, semiconductors, and photovoltaic equipment [2][3] - The non-ferrous metals sector saw a significant increase of 4.05%, while non-bank financials and oil & petrochemicals rose by 3.27% and 2.95%, respectively [3] - The brain-computer interface sector experienced a surge, with multiple stocks hitting the daily limit [3] Institutional Insights - Huatai Securities anticipates a strengthening spring market, recommending investments in growth sectors such as electric equipment and renewable energy, as well as domestic demand improvement themes [4] - CITIC Securities suggests that the cross-year market will exhibit characteristics of "growth leading and liquor accumulating," with a focus on sectors like snacks and dairy [5] - Guoxin Securities predicts that 2026 will be a significant year for the market, supported by favorable macro policies and improving corporate earnings [6] Emerging Opportunities - Guoxin Securities highlights the potential for 2026 to be the year of reusable commercial rockets, driven by the need for cost-effective launch solutions [7] - Tianfeng Securities expresses optimism about the growth potential in high-end consumer sectors such as cosmetics, gold jewelry, and duty-free shopping [8]

本报记者 刘钊 1月6日开盘，A股脑机接口概念板块延续强势，多只个股快速封板。截至记者发稿，其中伟思医疗（688580.SH）、三 博脑科（301293）（301293.SZ)、翔宇医疗（688626.SH）、爱朋医疗（300753）（300753.SZ)、美好医疗（301363） （301363.SZ）等多只个股20cm涨停，麦澜德（688273.SH）、诚益通（300430）（300430.SZ）、熵基科技 （301330）（301330.SZ）、博拓生物（688767.SH）等多只个股涨幅居前。 | 물을 | 代码 | 名称 | | 最新 | 涨幅% ↓ | 涨跌 | 成交量 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 688580 | 伟思医疗 | 1 | 69.70 | 20.01 | 11.62 | 8.70万 | | 2 | 301293 | 三博脑科 | 1 | 84.94 | 20.01 | 14.16 | 2.63万 | | 3 | 688626 | 翔宇医疗 | 1 | 87.12 | 20.00 | 14.52 | ...

Core Viewpoint - The stock of Weisi Medical has experienced a consecutive two-day limit-up, indicating strong market interest and performance in the brain-computer interface sector [1] Group 1: Stock Performance - Weisi Medical's stock reached a limit-up at 9:51 AM today, with a trading volume of 603 million yuan and a turnover rate of 9.32% [1] Group 2: Company Developments - The company has accumulated technology in the brain-computer interface field, including video EEG signal synchronization and automatic recognition of multi-channel EEG caps [1] - The performance for Q3 2025 shows positive growth in both revenue and net profit year-on-year [1] - The sale of the old headquarters has helped to optimize the asset structure and recover funds [1] - The rehabilitation equipment fundraising project has been completed with surplus funds used to supplement working capital [1] Group 3: Market Trends - The recent increase in activity within the brain-computer interface sector is attributed to technological breakthroughs and policy support, positioning it as a new economic growth point [1]

1月6日盘中科创板股伟思医疗涨停，截至09:54，股价报69.70元，成交5.86亿元，换手率9.06%，振幅 10.00%。 科创板个股中，截至发稿上涨的有405只，下跌的有190只，涨停的有伟思医疗、翔宇医疗等，跌幅居前 的有新光光电、华曙高科、兴图新科等，分别下跌8.64%、8.30%、5.50%。 资金面上，伟思医疗上一交易日主力资金净流入7765.42万元，近5日净流入8384.72万元。 融资融券数据显示，该股最新（1月5日）两融余额为2.02亿元，其中，融资余额为2.02亿元，较上一个 交易日增加2034.02万元，增幅为11.21%；融券余额为15.10万元，较上一个交易日增加5.42万元，增幅 为56.00%。近10日两融余额合计增加2458.46万元，增幅为13.87%，其间融资余额增长13.89%，融券余 额下降7.01%。 从机构评级来看，近一个月该股获1家机构买入评级。12月25日西部证券发布的研报给予公司增持评 级。 （文章来源：证券时报网） ...

Core Viewpoint - The market is actively speculating on Weisi Medical, which has seen a 20.01% increase and has hit the trading limit for two consecutive days, driven by the brain-computer interface (BCI) concept [1] Company Summary - Weisi Medical has a strong product and technology reserve in the non-invasive brain-computer interface field, covering key technologies such as EEG signal acquisition, interference correction, transmission analysis, machine learning algorithms, and non-invasive electrodes [1] - The company has established a closed-loop neuro-rehabilitation system that encompasses the entire cycle of "diagnosis—treatment—rehabilitation" [1] Industry Summary - A breakthrough in BCI implantation technology has been achieved by Huashan Hospital affiliated with Fudan University, marking the successful completion of the first clinical trial for the first domestically produced and second globally available fully implanted, wireless, and fully functional BCI product [1] - Elon Musk's Neuralink plans to start large-scale production of BCI devices in 2026, aiming for nearly fully automated surgical procedures [1] - Merge Labs, supported by OpenAI CEO Sam Altman, is splitting off to focus on new technology routes that utilize ultrasound to read brain activity [1] - The BCI sector has been included in China's "14th Five-Year Plan" as a future industry, with the National Medical Insurance Administration requiring proper coding for innovative medical consumables like BCIs [1] - The National Medical Products Administration is set to implement industry standards for medical devices using BCI technology by 2026 [1]

Core Insights - The medical device sector is experiencing a strong upward trend, with the CSI All Index Medical Device Index rising by 1.25% and significant gains in key stocks such as Meihua Medical and Xiangyu Medical [1] - Neuralink, owned by Elon Musk, plans to begin large-scale production of brain-machine interface devices in 2026, aiming for a streamlined and automated surgical process [1] - The brain-machine interface has been included in China's 14th Five-Year Plan, with specific goals for technological breakthroughs by 2027 and industry strength by 2030 [1] Market Performance - The medical device ETF (159883) has seen a 1.16% increase, with net subscriptions exceeding 400 million units [1] - The latest net inflow into the medical device ETF is 274 million yuan [1] Industry Developments - Domestic high-end medical device market share is increasing, with over 70% penetration of domestic DR and ultrasound diagnostic equipment in grassroots medical institutions [2] - The brain-machine interface industry is expected to enter a growth phase, transitioning from research to commercialization, supported by policy and technological advancements [2] - The brain-machine interface market is projected to grow at a CAGR of 17% from 2025 to 2034, reaching an estimated $12.4 billion by 2034 [2] ETF Insights - The medical device ETF (159883) has the highest brain-machine interface content in the market, accounting for over 23% of its holdings, and focuses on innovative domestic companies [3] - The Hong Kong medical ETF (159366) tracks a medical theme index, providing exposure to high-quality assets in the medical device sector, including minimally invasive brain science and robotics [3]

Core Insights - The announcement by Elon Musk regarding Neuralink's mass production of brain-machine interface (BMI) devices has significantly boosted market confidence in the commercialization of this technology, leading to a surge in related A-share stocks on the first trading day of 2026 [2][3][10] Group 1: Market Reaction - On January 5, 2026, domestic BMI concept stocks collectively opened high, with companies like Beikang rising over 29.98% and several others hitting the daily limit of 20% [1] - The market's positive response reflects high expectations for the commercial prospects of brain-machine interfaces following Musk's announcements [2][3] Group 2: Neuralink's Developments - Neuralink has completed seven rounds of financing, raising over $1.3 billion, which is significant compared to the projected $2.9 billion global market size for BMIs in 2025 [3][4] - The company has achieved several milestones, including FDA approval for human clinical trials and the first human implantation of a BMI, marking its leadership in the field [3][4] Group 3: Clinical Advancements in China - 2025 was termed the "Year of Chinese Brain-Machine Interfaces," with numerous clinical breakthroughs in restoring motor and speech abilities for high-level paraplegics, visual reconstruction, and treatment of mental disorders [7][8][10] - Key clinical trials have been conducted by various institutions, demonstrating significant advancements in BMI technology and its applications [9] Group 4: Regulatory and Market Developments - The introduction of policies such as the inclusion of BMIs in medical insurance and the establishment of regulatory frameworks for BMI medical devices indicate a move towards commercialization [10] - In 2025, the Chinese BMI sector saw 24 financing rounds, a 30% increase year-on-year, signaling growing investor interest and confidence in the market [10] Group 5: Competitive Landscape - Despite the surge in stock prices, there are currently no pure-play BMI companies listed in China, with many firms still in the process of developing their products and seeking IPO opportunities [11][12] - Companies like Qiangnao Technology and Bori Kang are actively pursuing IPOs, indicating a competitive race to become the first publicly listed BMI company in China [12][13] Group 6: Future Outlook - The industry is expected to enter a commercialization phase in 2026, with a competitive landscape emerging as various companies aim to establish themselves in the market [14]

从资金流向上来看，当日AI医疗板块主力资金净流入24.71亿元，游资资金净流出18.2亿元，散户资金 净流出6.51亿元。AI医疗板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，1月5日AI医疗板块较上一交易日上涨4.68%，伟思医疗领涨。当日上证指数报收于 4023.42，上涨1.38%。深证成指报收于13828.63，上涨2.24%。AI医疗板块个股涨跌见下表： ...